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Objective: It remains controversial whether there is a gender difference in survival of patients with resected non–
small cell lung cancer.
Methods:We retrospectively analyzed 2770 patients (1689 men and 1081 women) with non–small cell lung can-
cer who underwent pulmonary resection between 1995 and 2005 at the National Cancer Center Hospital, Tokyo.
A gender difference in survival was studied in all patients, in those divided according to histology or pathologic
stage, and in propensity-matched gender pairs.
Results: There were no differences in background, such as preoperative pulmonary function, operation proce-
dures, or operative mortality. The proportions of adenocarcinoma and pathologic stage I in women were greater
than those in men (93.6% vs 61.7% and 71.4% vs 58.6%, respectively) (P< .001). Overall 5-year survival of
women was better than that of men (81% vs 70%, P<.001). In adenocarcinoma, the overall 5-year survival for
women was better than that for men in pathologic stage I (95% vs 87%, P< .001) and in pathologic stage II or
higher (58% vs 51%, P¼ .017). In non-adenocarcinoma, there was no significant gender difference in survival in
pathologic stage I (P ¼ .313) or pathologic stage II or higher (P ¼ .770). The variables such as age, smoking
status, histology, and pathologic stage were used for propensity score matching, and survival analysis of propen-
sity score-matched gender pairs did not show a significant difference (P ¼ .69).
Conclusion: Women had better survival than men; however, there was no survival advantage in propensity-
matched gender pairs. A gender difference in survival was observed only in the adenocarcinoma subset, suggest-
ing pathobiology in adenocarcinoma in women might be different from that of men.
GENERALTHORACIC SURGERYMost studies on gender-associated differences in lung cancer
have found that women have several characteristics that are
different from those in men, such as younger age at presen-
tation, larger proportions of nonsmokers and early-stage dis-
eases, and predominance of adenocarcinoma.1-6 However,
the influence of female gender on survival remains contro-
versial because it has been insisted that gender is not a signif-
icant prognostic factor in non–small cell lung cancer
(NSCLC), although gender has been associated with smok-
ing exposure, stage, histologic subtype, and therapeutic
management.7,8
We believe that a unique analysis with a large database
may help to clarify the influence of gender on survival.
The purpose of this study is to explore gender differences
in clinical characteristics and survival based on a retrospec-
tive analysis of patients with NSCLC who had undergone
lung resection in a single institute during an 11-year
period.
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From January 1995 to December 2005, 2800 patients underwent lung
resection for primary lung cancer at the National Cancer Center Hospital,
Tokyo. Among these, 2770 patients (1689 men and 1081 women) who un-
derwent lung resection for NSCLC were reviewed retrospectively. This
study was approved by the institutional review board.
Preoperative evaluation was done by means of history and physical
examination, posteroanterior and lateral chest radiographs, and blood tests,
including complete blood count and serum chemistries. Computed tomog-
raphy scans of the chest and upper abdomen (including the liver and adrenal
glands) were checked routinely. Bone scintigraphy and brain imaging were
performed in cases of suspicious symptoms. A pulmonary function test and
electrocardiography were checked routinely. Quantitative pulmonary venti-
lation and perfusion scan were performed in patients with marginal pulmo-
nary function. The evaluation of chronic diseases and consultation with the
corresponding physicians depended on the patients’ conditions.
Patients with clinical stages I and II and selected cases of stage IIIA un-
derwent lung resection via thoracotomy. Basically, neoadjuvant preopera-
tive therapy was not performed except for recent cases of superior sulcus
tumor. Patients with N2 disease that was detected intraoperatively received
postoperative adjuvant therapy. All patients were staged on the basis of the
International Union Against Cancer TNM Classification of Malignant Tu-
mors staging system published in 1997,9 and tumor histology was described
according to the World Health Organization classification.10 For tumors
of adenocarcinoma with a greatest dimension of 2 cm or less, Noguchi
and colleagues’ classification11 was used to describe the histopathologic de-
tails. Types A and B correspond to bronchoalveolar carcinoma in the World
Health Organization classification, whereas type C corresponds to adeno-
carcinoma with mixed subtypes, including bronchoalveolar carcinoma
and invasive adenocarcinoma. Types D, E, and F correspond to invasive
solid, acinar, and papillary adenocarcinoma, respectively.
Follow-up was achieved through periodic visits to the outpatient clinic un-
til the present time or patient’s death. Operative mortality was defined as
death during hospitalization for lung resection or within 30 days of operation.ardiovascular Surgery c Volume 137, Number 4 807
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The chi-square test was used to evaluate the significance of observed dif-
ferences in the proportions of patients in the various outcome categories.
Survival was measured from the date of operation, and the median survival
was calculated and plotted according to the Kaplan–Meier method. Differ-
ences in survivals between groups were compared with the log-rank test.
For balanced assignment of the included patients to correct gender con-
founding in survival, propensity score matching was used. The variables
such as age (continuous), smoking status (ever or never), histologic types
(adenocarcinoma, squamous cell carcinoma, large cell carcinoma, or others),
and pathologic stages (I, II, III, or IV) were used. These were selected on the
basis of their significant difference between both genders (Table 1). A coef-
ficient that was calculated by logistic regression analysis was multiplied to
each variable, and the sum of these values were the propensity score for in-
dividual patient.12 Gender pairs with equivalent propensity score were se-
lected by a 1-to-1 match. All survival comparisons and analyses were
performed using SigmaPlot (Systat Software Inc, San Jose, Calif).
RESULTS
Clinical Features, Histology, and Pathologic Staging
The clinical characteristics of 2770 patients are summa-
rized in Table 1. The distribution of histologic subtypes
was significantly different between the 2 genders: There
was more adenocarcinoma (93.6% vs 61.7%, P< .001)
and less squamous cell carcinoma (4.1% vs 30.3%, P<
.001) in women. The distribution of pathologic stages
showed a statistically significant gender difference in that
women had a disproportionate representation in stage I dis-
ease compared with men (71.4% vs 58.6%, P < .001)
(Table 1).
With regard to adenocarcinoma, which was the most fre-
quent histology (n ¼ 2054, 74.2%), there was a significant
difference in pathologic features between men and women.
There were more well-differentiated tumors (P< .001) in
women but more lymphatic (P ¼ .011) or vascular invasion
(P<.001) in men (Table 2). There were 844 T1 adenocarci-
nomas with a greatest dimension of less than 2 cm, and in-
formation regarding Noguchi’s types was available in 604
cases (71.6%). Women had more Noguchi’s type A or B
(P ¼ .000) and less Noguchi’s type D, E, or F (P ¼ .000)
(Figure 1).
Survival Analysis
Overall 5-year survivals for men and women were 70%
and 81%, respectively (Figure 2), and there was a statisti-
cally significant gender difference in survival (P< .001).
In adenocarcinoma, the overall 5-year survival was 84%
for women (n ¼ 1012) and 75% for men (n ¼ 1042) (P<
.001). However, there was no significant gender difference
in survival in non-adenocarcinoma (P ¼ .299) (Figure 3).
When the patients were divided into subsets according to
the combination of histology and pathologic stage, overall808 The Journal of Thoracic and Cardiovascular Su5-year survival of women was significantly better than that
of men in pathologic stage I (95% vs 87%, P< .001) and
pathologic stage II or higher (58% vs 51%, P¼ .017) within
adenocarcinoma (Figures 4, A and 5, A). On the other hand,
there was no significant gender difference in survival in
pathologic stage I (79% in men vs 74% in women, P ¼
.313) or pathologic stage II or higher (50% in men vs
48% in women, P ¼ .770) within non-adenocarcinoma
(Figures 4, B and 5, B).
TABLE 1. Characteristics of patients (n ¼ 2770) with resected non–
small cell lung cancer
Men
(n ¼ 1689)
Women
(n ¼ 1081)
P
value
Age (y) 64.8 62.8 <.001
FEV1.0 (%) 76.8  21.6 82.5  12.7 .33
Ever-smoker (%) 77.5 22 <.001
Elevated CEA levela (%) 28.2 21 <.001
Operative procedures
Wedge resectionþ
Segmentectomy
189 (11.2%) 134 (12.4%) .877
Lobectomy 1381 (81.8%) 921 (85.2%) .38
Pneumonectomy 119 (7.0%) 26 (2.4%) .665
Morbidity/mortality
Mortality 11 (0.65%) 6 (0.65%) .392
Serious complicationsb 11 (0.7%) 5 (0.5%) .523
Empyema with or without BPF 34 (2%) 4 (0.4%) <.001
Histology
Adenocarcinoma 1042 (61.7%) 1012 (93.6%) <.001
Squamous cell carcinoma 511 (30.3%) 44 (4.1%) <.001
Large cell carcinoma 97 (5.7%) 10 (0.9%) <.001
Others 39 (2.3%) 15 (1.4%) .077
Pathologic stage
CIS 2 (0.1%) 1 (0.1%)
p stage I 990 (58.6%) 772 (71.4%) <.001
p stage II 320 (18.9%) 111 (10.3%) <.001
p stage III 361 (21.4%) 190 (17.6%) .014
p stage IV 16 (1%) 7 (0.6%) .385
FEV, Forced expiratory volume; CEA, carcinoembryonic antigen; BPF, bronchopleu-
ral fistula; CIS, carcinoma in situ. aPreoperative CEA level>5 ng/mL. bRespiratory
complications that required ventilator assistance, cerebrovascular accident, congestive
heart failure, or acute myocardial infarction.
TABLE 2. Pathologic features of adenocarcinoma according to gender
status (n ¼ 2054)
Male (n ¼ 1042) Female (n ¼ 1012) P value
Differentiation
Well 524 (50.3%) 678 (67%) <.001
Moderate 345 (33.1%) 283 (28%) .11
Poor 173 (16.6%) 51 (5%) <.001
Lymphatic invasion
Present 489 (46.9%) 396 (39.1%) .011
Vascular invasion
Present 510 (48.9%) 369 (36.5%) <.001rgery c April 2009
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and more Noguchi’s type D, E, or F in men.Propensity Score Matching
The distribution of characteristics of propensity score-
matched gender pairs (n ¼ 539) were summarized in Table
3. They were well-matched gender pairs without significant
difference in clinical characteristics. There was no signifi-
cant gender difference in survival in propensity score-
matched gender pairs (P ¼ .69) (Figure 6).
DISCUSSION
We observed a significant survival difference between
men and women without notable differences in background,
such as preoperative pulmonary function, type of operation
procedure, or operative mortality. Although the better
survival of women in the present study is consistent with
several previous reports (Table 4), it can be inferred from
the survival analysis of propensity score-matched gender
pairs that gender is a marker of a certain risk group with dif-
ferent tumorigenesis rather than an independent prognostic
indicator.
Several factors can be considered to be interrelated with
the better survival of women: 1) histopathology; 2) internal
environment, such as hormonal or genetic status; and 3) in-
nate demographic characteristics or artifactual factors. It has
been reported that the impact of tumor histology on survival
is unclear. Alexiou and colleagues13 showed that squamous
cell type was an independent favorable predictor of survival,
whereas others have shown no survival difference based on
the cell type.14 Women showed a significantly larger propor-
tion of well-differentiated type adenocarcinoma (Table 2)
and Noguchi’s classification A or B (Figure 1). A high de-
gree of differentiation provides a relative survival advan-
tage,15 and survival is significantly longer even in patients
after recurrence with well-differentiated tumors than in those
with moderately or poorly differentiated tumors.16 The de-
gree of differentiation is related to the expression of tumor
suppressor gene, such as WW domain-containing oxidore-
ductase, and the reduced or absent expression of this gene
was observed in invasive adenocarcinoma.17 These results
reflect the notion that the degree of differentiation is relatedThe Journal of Thoracic and Cto biological aggressiveness at a genetic level. It is also sup-
ported by the report that epidermal growth factor receptor
mutation was correlated with subtypes of adenocarcinoma
and their histologic grade.18 On the basis of the subset anal-
yses according to the histology and survival analysis in pro-
pensity score matching, histology is assumed to be one of the
factors affecting the gender difference in survival.
The distinctive internal environment of women might be
related to their better survival. It has been reported that gen-
der-dependent differences in estrogen receptor alpha and
beta expression could contribute to unique phenotypic char-
acteristics of lung cancer in women.19 Likewise, parathyroid
hormone-related protein, which predicts longer survival in
women but not in men, showed a more intense tumor sup-
pression effect in an NSCLC model in female mice because
it was regulated negatively by androgen hormone.20 Along
with hormonal influences, genes such as p53R172H?g/þ
K-rasLA1/þ have been recognized to be associated with
aggressive behavior and even a gender difference in cancer-
related death.21
FIGURE 2. Survival curves according to gender. The overall 5-year sur-
vival is 81% for women (n¼ 1081) and 70% for men (n¼ 1689). Women
show significantly better survival than men (P< .001).ardiovascular Surgery c Volume 137, Number 4 809
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75% for men (n ¼ 1042) and 84% for women (n ¼ 1012). This gender difference is significant (P< .001). In non-adenocarcinoma, the overall 5-year sur-
vivals of men (n ¼ 647) and women (n ¼ 69) are 64% and 58%, respectively. This gender difference in survival is not significant (P ¼ .299).Several artifactual factors might be related to the gender
difference in survival.22 The demographics of Japan are
changing so rapidly that life expectancy is increasing for
women. Furthermore, a favorable mix of demographic vari-
ables, such as good performance status, more asymptomatic
or screen-detected diseases, and fewer comorbidities, might
affect the better survival of women, although such informa-
tion was not available in this study.
One of the most remarkable results of this study is that
women show better survival than men even within subsets
of the same pathologic stage within adenocarcinoma, but
on the other hand no difference was observed in non-adeno-
carcinoma subsets. One possible explanation for this result is
a difference in smoking status. In contrast with non-adeno-
carcinoma, in most cases, adenocarcinoma in women arises
in the absence of the carcinogenic effect of tobacco, or at
least under the influence of only secondhand smoke from
the spouse or workplace. This could be responsible for the
difference in tumorigenesis and pathobiological activity of
adenocarcinoma in women. In addition to this difference
in smoking status, women are often exposed to different ex-
ternal environments, such as cooking fumes from fuels and
oils, household pollutants, and industrial dust. Ko and col-
leagues23 suggested that the frequency of exposure to fumes
from cooking oils, when not reduced by an extractor, might
be an important factor in lung cancer in nonsmoking women.
FIGURE 4. Survival curves according to gender of pathologic stage I in adenocarcinoma (A) and non-adenocarcinoma (B). The overall 5-year survival of
pathologic I in adenocarcinoma for women is significantly better than that for men (95% vs 87%, P< .001). There is no significant gender difference in
survival of pathologic stage I in non-adenocarcinoma (79% vs 74%, P ¼ .313).810 The Journal of Thoracic and Cardiovascular Surgery c April 2009
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underlie the difference in adenocarcinoma in women.
On the basis of the results regarding gender differences in
the pathologic features of adenocarcinoma or survival anal-
yses in subsets, adenocarcinoma in women is presumed to
have different pathobiologic behaviors from that in men.
Genetic polymorphisms, familial susceptibility, and the
mutation of specific genes are now being investigated as
possible causes of the biological differences in adenocarci-
noma in women.24-26 Further investigations are needed on
the pathologic and biological nature of adenocarcinoma in
women.
CONCLUSIONS
There is significant gender difference in survival after re-
section of NSCLC. Women show significantly better overall
5-year survival than men in all patients and in subsets of ad-
enocarcinoma within the same pathologic stage, but there
was no survival advantage of women in propensity-matched
gender pairs. The pathobiology in adenocarcinoma in
women might be different from that in men.
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